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ABSTRACT The x-ray crystal structure of the serpin-proteinase complex is yet to be determined. In this study we have
investigated the conformational changes that take place within antitrypsin during complex formation with catalytically inactive
(thrombinS195A) and active thrombin. Three variants of antitrypsin Pittsburgh (an effective thrombin inhibitor), each containing
a unique cysteine residue (Cys232, CysP3, and Cys313) were covalently modified with the fluorescence probe N,N-dimethyl-
N-(iodoacetyl)-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine. The presence of the fluorescent label did not affect the
structure or inhibitory activity of the serpin. We monitored the changes in the fluorescence emission spectra of each labeled
serpin in the native and cleaved state, and in complex with active and inactive thrombin. These data show that the serpin
undergoes conformational change upon forming a complex with either active or inactive proteinase. Steady-state fluores-
cence quenching measurements using potassium iodide were used to further probe the nature and extent of this confor-
mational change. A pronounced conformational change is observed upon locking with an active proteinase; however, our
data reveal that docking with the inactive proteinase thrombinS195A is also able to induce a conformational change in the
serpin.
INTRODUCTION
Serpins are a unique family of proteinase inhibitors (Po-
tempa et al., 1994) that in contrast to the standard-mecha-
nism inhibitors, such as the small Kunitz and Kazal inhib-
itors (Bode and Huber, 1992), achieve inhibition of their
target proteinase via a mobile reactive center loop (RCL).
Although the conformation of the RCL during the inhibitory
process is not known, its ability to assume different confor-
mations is important in inhibition (Hopkins and Stone,
1995). In native serpins (Fig. 1 a) the RCL is poised at the
top of the molecule ready to interact with the target pro-
teinase. Upon proteolytic cleavage within the RCL region,
the molecule opens up and the RCL is incorporated as the
fourth strand of the large central A -sheet (Fig. 1 b). This
conformational change, termed the stressed to relaxed tran-
sition (S to R) is accompanied by a dramatic increase in heat
stability and resistance to denaturants such as urea or gua-
nidine hydrochloride (Mast et al., 1992). The x-ray crystal
structures of two structural intermediates involved in this
transition have been determined in which the RCL is par-
tially inserted. In native antithrombin two residues are in-
serted into the top of the A -sheet (Fig. 2 a) (Schreuder et
al., 1994; Carrell et al., 1994; Skinner et al., 1997). The
recently determined structure of antichymotrypsin
Leu55Pro adopted an unusual conformation (termed ), in
which four residues of the RCL occupy the top half of the
A -sheet and the F-helix unwinds to occupy the bottom
half of the sheet (Fig. 2 b) (Gooptu et al., 2000). The
identification of these intermediates is critical, because it
provides direct crystallographic evidence that it is possible
for the serpin to adopt transitional states along the pathway
of conformational change.
Lawrence and colleagues (1995) elegantly demonstrated
that RCL cleavage at the scissile bond is critical for the
formation of the final locked complex between serpin and
proteinase. Furthermore, they proposed that the conforma-
tional change within the serpin is essential for trapping the
proteinase at the acyl-enzyme step in the proteinase cleav-
age pathway. Several studies have shown that serpin con-
formational mobility and RCL insertion are crucial for
efficient proteinase inhibition (Hopkins and Stone, 1995;
Picard et al., 1999; Shore et al., 1995; Stratikos and Gettins,
1997, 1999; Wilczynska et al., 1997). For example, numer-
ous mutations within the RCL have been shown to result in
substrate-like behavior (for review see Stein and Carrell,
1995). It is proposed that such mutations disrupt efficient
loop insertion and thus allow the proteinase to escape inhi-
bition (Hopkins et al., 1993; Hopkins and Stone, 1995).
Recent biophysical studies have played a major role in
elucidating the structure of the serpin-proteinase complex
(Wilczynska et al., 1997; Stratikos and Gettins, 1997, 1998,
1999), with a consensus emerging that the proteinase is
translocated to the bottom of the serpin (Wright, 1996) (Fig.
2 c). Although it is clear that RCL insertion into the A
-sheet is a requirement for successful inhibition, the mech-
anism by which loop insertion is triggered remains unclear
(Stone and Le Bonniec, 1997).
In this study we use a combination of site-directed mu-
tagenesis, fluorescence labeling and fluorescence quenching
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techniques to probe the structure of the complex further.
Specifically we investigated the interaction between antit-
rypsin Pittsburgh (denoted 1PI in this study) which pos-
sesses a P1  Arg and thrombin. This serpin was used
because it has high affinity for both thrombin and inactive
thrombin (thrombinS195A), therefore providing us with the
opportunity to examine both the Michaelis-complex (EI)
and final covalent complex (EI†). Using both these thrombin
forms allows us to gain insight into the structure of the
initial docking complex (Cooperman et al., 1993; O’Malley
et al., 1997; Stone and Le Bonniec, 1997) formed between
the serpin and proteinase and then the conformational
changes involved in final inhibition.
MATERIALS AND METHODS
N,N-dimethyl-N-(iodoacetyl)-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)eth-
ylenediamine (IANBD) were purchased from Molecular Probes (Eugene,
OR). Thrombin was purified from human plasma and characterized as
previously described (Stone and Hofsteenge, 1986), and thrombin(S195A)
was purified and characterized as previously described (Le Bonniec et al.,
1993; Stone and Le Bonniec, 1997).
Production of 1 PI variants
The construction, expression, and purification of 1PI and the two 1PI
variants Cys313 and CysP3 has been described (James et al., 1999; Bot-
tomley et al., 1998). The association rate constant (kass) and stoichiometry
of inhibition (SI) were measured using thrombin for both the unlabeled and
labeled antitrypsin forms, as described previously (Le Bonniec et al.,
1995). Fluorescent labeling of the proteins with IANBD was performed as
previously described (James et al., 1999). The extent of labeling was
determined using the extinction coefficient of IANBD (  25,000 M1
cm1). Cleaved antitrypsin was produced by cleavage with papain and
purification by ion-exchange chromatography using Q-Sepharose.
FIGURE 2 Schematic showing RCL insertion in serpins. Only the A-
sheet (gray) and the RCL (black) are shown. (a) Native antithrombin, in
which two residues (P15-P14) are partially inserted into the A -sheet. A
water molecule (), located in the gap between strands s3A and s5A,
forms hydrogen bonds to each of these strands. (b) Leu55Pro antichymo-
trypsin (Gooptu et al., 2000), in which four residues of the RCL (P15-P12)
are inserted into the top half of the sheet. The bottom half of the sheet is
occupied by residues that originally formed part of the F-helix (dashed
line), thus fully satisfying the hydrogen bond pattern within the A -sheet.
(c) Full insertion with proteinase (P) attached.
FIGURE 1 X-ray crystal structures of 1PI. (a) Native 1PI. The -sheets and -helices are labeled, and the RCL is shown in black at the top of the
molecule.The RCL is numbered according to standard nomenclature (Pn. . . P3-P2-P1-P1-P2-P3. . . Pn; (Schechter and Berger; 1967), P1-P1 being the
scissile bond cleaved by the proteinase. (b) Cleaved 1PI. The RCL is buried in the center of the A -sheet.
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Spectroscopic methods
Fluorescence emission spectra were recorded on a Perkin-Elmer LS50B
spectrofluorimeter, using a thermostatted cuvette holder at 37°C in a
1-cm-path-length quartz cell. Excitation and emission slits were set at 2.5
nm for all spectra and a scan speed of 10 nm/min was used. The absorbance
at the excitation wavelengths was monitored in all experiments and re-
mained below 0.05 units.
Steady-state fluorescence quenching
Fluorescence quenching measurements were performed in 50 mM Tris, pH
8.0, at 37°C. Aliquots of KI (2 M stock) containing 1 mM Na2S2O3 were
added to protein solutions (200 nM) and the change in fluorescence
emission intensity of the covalently bound IANBD (ex  480 nm) was
measured. All fluorescence data were corrected for sample dilution. The
quenching data were analyzed by the Stern-Volmer equation as previously
described by Lehrer (1971). All data were corrected for inner filter effects
where necessary.
Coordinates and model building
The coordinates of wild-type native (Elliott et al., 1996) (pdb identifier
1QLP) and cleaved (Loebermann et al., 1984) (protein data bank (PDB)
identifier 7API) antitrypsin, native antithrombin (Schreuder et al., 1994;
Carrell et al., 1994; Skinner et al., 1997) (PDB identifier 2ANT), and
thrombin (Qiu et al., 1992) (PDB identifier 1ABJ) were obtained from the
protein data bank (www.rcsb.org). Previous studies by Elliott et al. (1996)
have demonstrated that the RCL of antitrypsin adopts a canonical confor-
mation (Hubbard et al., 1991) and can be docked into the active site of
chymotrypsin with relatively few steric clashes. We used similar superpo-
sition and modeling techniques to that described previously (Elliott et al.,
1996; Whisstock et al., 1996) to dock antitrypsin into the active site of
thrombin. Briefly, the P1 methionine residue was changed to an arginine
using the mutate facility in Quanta (MSI, San Diego, CA). The P1 of the
proteinase inhibitor D-Phe-Pro-Arg chloromethylketone (PPACK) in the
active site of thrombin was used as a template to position the P1 arginine
residue of antitrypsin into the S1 subsite of thrombin. The PPACK mole-
cule was then removed to leave a model of antitrypsin P1  Arg docked
to thrombin. Several side-chain clashes were observed between the pro-
teinase and the body of the serpin, and these were resolved by subjecting
the model to rounds of CHARMm minimization until convergence was
reached. The stereochemistry of the model was checked and all residues
found to be in allowed conformations.
To build EI we used the x-ray crystal structure of native antithrombin
as a template in the program MODELLER (Sali and Blundell, 1993) to
construct a model of antitrypsin in which the RCL is partially inserted to
P14. The RCL of antithrombin is three residues longer that that of anti-
trypsin and in a noncanonical conformation. To maintain a canonical loop
in our model of partially inserted antitrypsin, the RCL was rebuilt, using
the structure of native antitrypsin as a template. A similar superposition
procedure to that previously described was used to generate a model
between thrombin and antitrypsin Pittsburgh in which the RCL is partially
inserted to P14. We observed few steric clashes between the proteinase and
inhibitor, and these were resolved by rounds of CHARMm minimization.
The stereochemistry of the model of EI was checked and all residues were
in allowed conformations
RESULTS
Previous kinetic studies have identified a number of inter-
mediates involved in the serpin-proteinase inhibitory path-
way (Fig. 3) (O’Malley et al., 1997; Stone et al., 1997;
Stone and Le Bonniec, 1997). The aim of this study was to
determine the structural changes of 1PI as it passes through
this inhibitory pathway. To achieve this goal, we have
characterized four different conformers of 1PI–native (I),
noncovalent complex (EI; formed with thrombinS195A), co-
valent complex (EI†; formed with active thrombin), and
cleaved (I*) (Fig. 3). Each of the four conformers was
formed using three 1PI variants, which were specifically
labeled at different sites with an environmentally sensitive
fluorophore (IANBD). The three Pittsburgh variants of 1PI
used in the study contained a unique single cysteine residue
(see Fig. 6) positioned either at the top (1PI-CysP3), bot-
tom (1PI-Cys313), or rear (1PI-Cys232) of the molecule.
Cys232, the native cysteine residue of 1PI, was mutated to
a serine in both 1PI-CysP3 and 1PI-Cys313, and this was
shown to have no effect upon the inhibitory properties of the
proteins (James et al., 1999). Each of the three variants were
expressed, purified, and covalently modified with IANBD
as previously described (James et al., 1999). The labeling
stoichiometry was 1:1 in all cases, and kinetic experiments
demonstrated that the IANBD labeling has no effect upon
the kass and SI with thrombin. In addition, SDS-PAGE
analysis of the complex formed between the variants and
thrombin at a 1:1 ratio demonstrated the presence of a single
complex band (Fig. 4). Furthermore, far-UV circular di-
chroism and tryptophan emission spectra of all the labeled
and unlabeled proteins were identical, suggesting that mu-
tagenesis and IANBD labeling did not alter the structure of
the serpin (data not shown). Indeed, previously we have
shown that the IANBD modification does not affect the
unfolding and refolding pathways of the variants (James et
al., 1999). Taken together, these biochemical and biophys-
ical data strongly suggest that the presence of the IANBD
moiety had a negligible effect on the structural and inhibi-
tory properties of the proteins.
The presence of the fluorescence probe IANBD provides
the protein with new fluorescence properties (Fig. 5, Table
1). In the native state the emission maximum (max) relates
the position of IANBD within the protein. The labeled
wild-type protein, 1PI-Cys232, has an emission maximum
at 531 nm, whereas 1PI-Cys313 and 1PI-CysP3 were at
529 nm and 532 nm, respectively. These data indicate that
the label on 1PI-Cys313 is more protected from the solvent
than the corresponding label on 1PI-Cys232 and that the
FIGURE 3 Kinetic scheme summarizing serpin-proteinase complex for-
mation. E, proteinase; I, serpin; EI, the noncovalent Michaelis complex;
E-I, acyl enzyme intermediate before partitioning; E-I† covalent complex;
I*, cleaved serpin. This scheme uses the nomenclature described by Stra-
tikos and Gettins (1999).
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label attached to 1PI-CysP3 is highly solvent exposed on
the RCL. The solvent environment of the probe is reflected
in its max, and so it is a useful indicator of structural
change. Fig. 5 shows the emission spectra of all three
proteins in four different conformations. The cleaved state
of the protein was made by incubation of the serpin with
papain. The cleaved serpin was then isolated by ion-ex-
change chromatography. The max of the cleaved states
shows a number of changes in comparison with the native
state. The IANBD on 1PI-CysP3 and 1PI-Cys232 showed
no change upon cleavage, whereas a large change in max
was observed for the 1PI-Cys313 in which the max was
blue shifted by 6 nm compared with the native state. All of
these changes are consistent with the movement of a frag-
ment of 1PI caused by the insertion of the RCL into the A
-sheet as described recently (Whisstock et al., 2000). Upon
formation of the noncovalent complex (EI) with
thrombinS195A different changes in the max of the IANBD
label were observed. As expected from the position of
Cys232 at the back of the molecule 1PI-Cys232 showed no
change in max with thrombinS195A. However, 1PI-Cys313
displayed a shift in max of 4 nm, indicating that upon
formation of EI the region at the base of the molecule
undergoes a conformational change, similar to that seen in
the cleaved state. 1PI-CysP3 also displayed a change in
max, a blue shift of 2 nm, indicating that the probe became
less solvent exposed upon formation of EI. Formation of
the final serpin-proteinase complex indicated further con-
formational change within the serpin. The max of 1PI-
CysP3 and 1PI-Cys232 in complex with thrombin were
identical to that of the cleaved and native states. Thrombin
in complex with 1PI-Cys313 exhibited a max of 531 iden-
tical to that observed with thrombinS195A but not as high as
that seen in the cleaved state (max  533 nm).
Another sensitive fluorescent approach that can reveal
much about conformational change and protein-protein in-
teractions is fluorescence quenching (Eftink and Ghiron,
1981). Both iodide and cesium were used as quenching
agents to examine the structural transitions of the three
variants during proteinase inhibition. Cesium, which is pos-
itively charged, was unable to quench the fluorescence of
the IANBD moiety of all three variants in any form (data
not shown). Iodide, however, was found to be an efficient
quencher of the IANBD fluorescence. Fig. 5 shows a Stern-
Volmer plot for each variant in each conformation (Lehrer,
1971), and from these plots the Stern-Volmer (Ksv) quench-
ing constant was determined (Table 1). The iodide quench-
ing yielded linear Stern-Volmer plots (Fig. 5), which im-
plies that the fluorescence quenching takes place on a
simple collisional basis. The Ksv for the native 1PI-CysP3
was 5.8 M1, whereas the cleaved and complex with throm-
bin forms were similar (7.0 M1), indicating increased
accessibility of the IANBD probe in these states compared
with native. In the presence of thrombinS195A, however, the
Ksv is significantly decreased to 4.7 M1. These data dem-
onstrate that the IANBD label in the EI form is less acces-
sible either due to a conformational change or because the
inactive proteinase is preventing access for the quenching
agent. There are only minor changes in Ksv seen for the
1PI-Cys232 conformations, suggesting that this region of
the protein does not undergo any conformational change or
that the active or inactive proteinase does not come into
close proximity. 1PI-Cys313 shows changes in Ksv upon
both complex formation and RCL cleavage. The conforma-
tional states of EI, EI†, or I* all exhibited similar Ksv values
of approximately 8.8 M1, significantly higher than the
native value of 7.4 M1. These data indicate that the region
around Cys313 undergoes a conformational change upon
formation of EI and EI† that is similar to that seen upon
cleavage of the RCL.
DISCUSSION
The minimal kinetic scheme presented in Fig. 3 illustrates
the complexity of the serpin inhibitory pathway. Using the
combination of 1PI with both active and inactive protein-
ase, we have been able to form specific conformations along
the pathway for study. The conformations of intact 1PI (I)
and RCL cleaved 1PI (I*) have been crystallographically
characterized (Fig. 1) and are easily studied. The I and I*
states represent the extremes of RCL insertion, i.e., no
insertion (I) and full insertion (I*). The final covalent com-
plex (EI†) is formed between 1PI and active thrombin, and
the initial Michaelis complex (EI) is formed with
thrombinS195A. In this study we have used a combination of
protein engineering and fluorescence spectroscopic tech-
niques to examine the structure of 1PI in these four states.
FIGURE 4 SDS-PAGE of reaction between 1PI- Cys313 and thrombin.
1PI- Cys313 and thrombin at 1:1 ratio were incubated at 37°C for 30 min
and then analyzed by 10% SDS-PAGE. Lane 1, free 1PI- Cys313; lane 2,
thrombin; lane 3, the complex between 1PI- Cys313 and thrombin.
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Analysis of the native and cleaved states of 1PI
The fluorescence approach used here shows that upon the S
to R transformation a considerable conformational change
takes place. There is no structural change around Cys232,
and this is supported by structural analysis of both I and I*.
Cys232 is located on the B -sheet, a region not associated
with any structural reorganization during formation of the
stable complex. Indeed, a structural comparison between
native and cleaved antitrypsin revealed that this region
forms part of the rigid scaffold upon which most serpin
conformational changes occur (Stein and Chothia, 1991;
James et al., 1999; Whisstock et al., 2000). The Cys residue
of 1PI-CysP3, situated at the C-terminal end of the RCL,
shows a small blue shift (2 nm) in max upon RCL cleavage
and an increase in Ksv, indicating increased accessibility to
the quenching agent iodide. The most significant changes
observed, however, were around Cys313, which is situated at
the base of the serpin molecule on a loop connecting strands
5A and 6A of the A -sheet. Upon RCL insertion there was
a large red shift in the max (6 nm) of 1PI-Cys313 and an
increase in Ksv. These data suggest significant movement in
this region that increases the exposure of the IANBD label
to solvent and subsequently enhances its accessibility to the
iodide quenching agent. A structural comparison between
native and cleaved 1PI revealed that the loop containing
residue 313 is part of a rigid fragment that shifts signifi-
cantly during the S to R transition (Whisstock et al., 2000).
Thus, the fluorescent changes we observe between the na-
tive and cleaved form of the 1PI-Cys313 are entirely con-
sistent with RCL insertion and the S to R transition.
Analysis of the conformation of EI
The EI state, formed between 1PI and thrombinS195A, is
equivalent to the Michaelis complex. Previously it has been
shown that the affinity between the two was high enough
(KI  3  106 M) (Stone and Le Bonniec, 1997) to allow
formation of the complex and its study. The conformational
changes involved in forming EI have generally been in-
ferred from kinetic studies (Stone and Le Bonniec, 1997).
However, work by Gettins and co-workers using 1PI and
anhydrotrypsin suggested that no significant conformational
change occurs upon formation of the noncovalent complex
(Stratikos and Gettins, 1998, 1999). In this study we found
TABLE 1 max and iodide quenching parameters for the IANBD-labeled 1PI in four different conformations
Species
1PI-CysP3 1PI-Cys232 1PI-Cys313
max (nm) KSV (M1) max (nm) KSV (M1) max (nm) KSV (M1)
Native (I) 532 5.8  0.06 531 9.0  0.08 527 7.4  0.04
Plus thrombinS195A (EI) 530 4.7  0.07 531 9.2  0.08 531 8.5  0.09
Plus thrombin (EI†) 532 7.0  0.06 531 9.7  0.08 531 9.2  0.08
Cleaved (I*) 532 7.0  0.06 532 10.4  0.09 533 8.8  0.09
Each value is the average of seven separate experiments.
FIGURE 5 Fluorescence emission spectra and Stern-Volmer quenching of 1PI-labeled variants. The fluorescence emission spectra (ex  480 nm) of
the 1PI variants are shown in the native (f), cleaved (), noncovalent complex with thrombin(S195A) (), and thrombin (Œ). The Stern-Volmer plots for
the same samples are also shown (same symbols as above). Each point is an average of five data points and from three different protein preparations. The
data were analyzed by the Stern-Volmer equation (Lehrer, 1971).
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that the fluorescence of the IANBD label at CysP3 was
altered due to formation of EI. This was demonstrated by
the blue-shifted max and the decreased accessibility of the
quenching agent. The changes in Ksv must be due to the
proximity of the inactive proteinase, as similar changes are
not seen in the cleaved state. A significant difference be-
tween the previous (Stratikos and Gettins, 1999) and our
present study is that we observed a conformational change
around Cys313 upon EI formation. This manifested itself in
a 4-nm red shift in max and an increase in Ksv, indicative of
its increased solvent exposure. In contrast to the changes
observed with 1PI-CysP3, these changes are due to a
conformational change in the serpin as they are similar to
those observed in the cleaved state. Therefore the docking
of E to I, leading to the formation of EI, results in insertion
of the RCL into the A -sheet, which results in movement
at the base of the serpin. Additional evidence for this change
comes from a recent structural comparison between intact
and cleaved 1PI, which showed that this region at the base
of the molecule, which includes Cys313, is required to move
upon RCL insertion (Whisstock et al., 2000). These data
confirm the kinetic data produced earlier that suggested that
proteinase docking was enough to trigger RCL insertion
(Stone and Le Bonniec, 1997).
What is the extent of RCL insertion in EI? The structures
of native antithrombin and the  conformation of Leu55Pro
antichymotrypsin reveal that the serpin structure is able to
adopt at least two different partially inserted conformations
(Fig. 2, a and b) (Schreuder et al., 1994; Carrell et al., 1994;
Skinner et al., 1997; Gooptu et al., 2000). Previous model-
ing studies have shown that RCL insertion in antitrypsin
beyond P14 without cleavage is not sterically feasible un-
less the first strand of the C-sheet (s1C) is released (Whis-
stock et al., 1996). This prediction is supported by the
structure of  antichymotrypsin in which s1C is distorted to
allow RCL insertion to P12 (Gooptu et al., 2000). The
antichymotrypsin RCL is four residues longer than that of
1PI, suggesting that extensive distortion of s1C would be
required for RCL insertion to P12 in 1PI. A superposition
of native 1PI and native antithrombin (in which the RCL is
inserted to P14) reveals that a substantial conformational
change accompanies the insertion of just two residues
(Whisstock et al., 1996). Furthermore, these data reveal a
shift in the rigid fragment containing residue 313. We
therefore predict that the initial encounter complex forma-
tion between 1PI and thrombinS195A (Fig. 6 a) triggers
RCL insertion to P14 to form a stable noncovalent complex
(Fig. 5 b). We cannot, however, exclude the possibility of
further RCL insertion in the noncovalent complex with the
concurrent release of s1C.
Analysis of EI†
Our data describe a covalent complex in which the protein-
ase has moved from the top of the serpin to some position
on the A -sheet of the molecule. Our data are not sufficient
to place the proteinase in a specific position, although we
are able to narrow down its location with respect to the
serpin. The max of 1PI-CysP3 in complex with thrombin
is similar to the native state, suggesting a similar solvent
environment for the probe in both states (i.e., not covered by
the proteinase in the complex). The Ksv value of the EI†
form is the same as the cleaved state, suggesting that the
C-terminal residues of the scissile bond are in a similar
environment. Therefore, the proteinase has moved signifi-
cantly from its initial docking position. Our data with the
1PI-Cys313 indicate that thrombin is not situated directly
over this residue at the base of the serpin. This is due to the
increased solvent exposure of the label on 1PI-Cys313 in
the presence of thrombin. This is in contrast to recent results
from experiments that placed a probe at Cys314 and found it
covered by trypsin. Trypsin is a much smaller proteinase
than thrombin and this may go some way toward explaining
the difference (Stratikos and Gettins, 1999).
In conclusion, the data presented here using 1PI and
thrombinS195A clearly demonstrate that proteinase docking
is enough to trigger RCL insertion into the A -sheet, which
has allowed us to present a model of the initial docking
complex. However, although we are not able to precisely
map the position of the proteinase in the final covalent
complex it is clear that it has significantly moved from its
initial position at the top of the serpin.
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FIGURE 6 Molecular model of the initial docking complex (a) and
noncovalent Michaelis complex EI (b). The A -sheet is in red, the B
-sheet in green, and the C -sheet in yellow. The RCL is labeled and in
magenta. Residues 232, 313, and P3 are represented by van der Waal
spheres. The proteinase is at the top of the figure in light green. We predict
that initial docking (a) is followed by RCL insertion to P14 (b).
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